We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
- Authors
Brahmer, Julie R; Drake, Charles G; Wollner, Ira; Powderly, John D; Picus, Joel; Sharfman, William H; Stankevich, Elizabeth; Pons, Alice; Salay, Theresa M; McMiller, Tracee L; Gilson, Marta M; Wang, Changyu; Selby, Mark; Taube, Janis M; Anders, Robert; Chen, Lieping; Korman, Alan J; Pardoll, Drew M; Lowy, Israel; Topalian, Suzanne L
- Abstract
Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 19, p3167
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.26.7609